Immunotherapy could be used to treat depression, early trial suggests
An early clinical trial suggests that tocilizumab, an anti-inflammatory drug, may be effective in treating depression for patients who do not respond to traditional antidepressants. The study involved 30 participants and indicated that those receiving tocilizumab showed greater improvements in depression symptoms compared to those given a placebo. Researchers believe this could represent a significant step towards more personalized treatment options for depression.
- ▪The trial involved 30 participants with moderate to severe depression who had not responded well to standard antidepressants.
- ▪Participants treated with tocilizumab were more likely to achieve depression remission compared to the placebo group, at 54% versus 31%.
- ▪The study is one of the first to test immunotherapy for depression and shows potential for tailored treatment approaches.
Opening excerpt (first ~120 words) tap to expand
Participants who received tocilizumab seemed to experience greater improvements over time compared with those given a placebo. Photograph: Pascal Rossignol/ReutersView image in fullscreenParticipants who received tocilizumab seemed to experience greater improvements over time compared with those given a placebo. Photograph: Pascal Rossignol/ReutersDepressionImmunotherapy could be used to treat depression, early trial suggestsUK scientists find tocilizumab, used for rheumatoid arthritis, may help antidepressant-resistant patientsTobi Thomas Health and inequalities correspondent Wed 20 May 2026 11.00 EDTSharePrefer the Guardian on GoogleImmunotherapy could be used to treat depression among patients who have not responded to conventional antidepressants, according to the results of an early…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — Science.
Discussion
0 commentsMore from The Guardian — Science
